Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 97 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 7
Therapeutics Development 8
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 8
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis 9
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 10
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Gilead Sciences, Inc. 15
Novartis AG 16
Nippon Shinyaku Co., Ltd. 17
CTI BioPharma Corp. 18
Incyte Corporation 19
Italfarmaco S.p.A. 20
Promedior, Inc. 21
Pharma Mar, S.A. 22
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
pacritinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
momelotinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ruxolitinib phosphate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PRM-151 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
plitidepsin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LCL-161 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
luminespib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
givinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
simtuzumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
INCB-39110 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AZD-1480 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
panobinostat - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NS-018 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
buparlisib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Recent Pipeline Updates 67
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 91
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 92
Featured News & Press Releases 92
Dec 07, 2012: Incyte Announces Presentation Of New Data For Jakafi At 2012 American Society Of Hematology Annual Meeting 92
Aug 28, 2012: Incyte's Partner Novartis Receives European Approval For Jakavi 93
Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting 93
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2014 8
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by AstraZeneca PLC, H2 2014 14
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H2 2014 15
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H2 2014 16
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 17
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp., H2 2014 18
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H2 2014 19
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H2 2014 20
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H2 2014 21
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pharma Mar, S.A., H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Recent Pipeline Updates, H2 2014 67
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H2 2014 91